> top > docs > PubMed:18289055 > annotations

PubMed:18289055 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-137 Sentence denotes Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis.
T2 138-445 Sentence denotes Matrix metalloproteinases (MMPs) are a large family of proteolytic enzymes involved in an array of physiological and pathological processes from development, morphogenesis, reproduction, wound healing, and aging to inflammation, angiogenesis, neurological disorders, and cancer cell invasion and metastasis.
T3 446-594 Sentence denotes The imbalance between MMP activity and the inhibitory action of tissue inhibitors of metalloproteinases (TIMPs) are implicated in multiple diseases.
T4 595-921 Sentence denotes Secreted in the body in a latent form, upon activation MMP-9 (gelatinase B) acts on many inflammatory substrates, and thus is suspected of contributing to the progression of cardiovascular disease, rheumatoid arthritis, and the subjects of this review, chronic obstructive pulmonary disease (COPD) and multiple sclerosis (MS).
T5 922-989 Sentence denotes COPD is the fourth most common cause of death in the United States.
T6 990-1149 Sentence denotes In COPD, increased expression of MMP-9 by inflammatory cells e.g. neutrophils and macrophages is correlated with a variety of processes that cause lung damage.
T7 1150-1315 Sentence denotes MMP-9 is also important in cytokine and protease modulation; it degrades the serine protease inhibitor alpha(1)-antitrypsin, which thus may lead to lung destruction.
T8 1316-1395 Sentence denotes MS affects approximately 400,000 Americans and over a million people worldwide.
T9 1396-1612 Sentence denotes Upregulation of MMP-9 increases the permeability of the blood brain barrier (BBB), facilitates the infiltration of leukocytes into the central nervous system, and causes myelin sheath degradation and neuronal damage.
T10 1613-1700 Sentence denotes Early stage clinical trials have shown promising results when MMP-9 is inhibited in MS.
T11 1701-1886 Sentence denotes These observations lead to the hypothesis that MMP-9 is a potential drug target for both COPD and MS and further development of highly potent and specific MMP-9 inhibitors is warranted.
T1 0-137 Sentence denotes Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis.
T2 138-445 Sentence denotes Matrix metalloproteinases (MMPs) are a large family of proteolytic enzymes involved in an array of physiological and pathological processes from development, morphogenesis, reproduction, wound healing, and aging to inflammation, angiogenesis, neurological disorders, and cancer cell invasion and metastasis.
T3 446-594 Sentence denotes The imbalance between MMP activity and the inhibitory action of tissue inhibitors of metalloproteinases (TIMPs) are implicated in multiple diseases.
T4 595-921 Sentence denotes Secreted in the body in a latent form, upon activation MMP-9 (gelatinase B) acts on many inflammatory substrates, and thus is suspected of contributing to the progression of cardiovascular disease, rheumatoid arthritis, and the subjects of this review, chronic obstructive pulmonary disease (COPD) and multiple sclerosis (MS).
T5 922-989 Sentence denotes COPD is the fourth most common cause of death in the United States.
T6 990-1149 Sentence denotes In COPD, increased expression of MMP-9 by inflammatory cells e.g. neutrophils and macrophages is correlated with a variety of processes that cause lung damage.
T7 1150-1315 Sentence denotes MMP-9 is also important in cytokine and protease modulation; it degrades the serine protease inhibitor alpha(1)-antitrypsin, which thus may lead to lung destruction.
T8 1316-1395 Sentence denotes MS affects approximately 400,000 Americans and over a million people worldwide.
T9 1396-1612 Sentence denotes Upregulation of MMP-9 increases the permeability of the blood brain barrier (BBB), facilitates the infiltration of leukocytes into the central nervous system, and causes myelin sheath degradation and neuronal damage.
T10 1613-1700 Sentence denotes Early stage clinical trials have shown promising results when MMP-9 is inhibited in MS.
T11 1701-1886 Sentence denotes These observations lead to the hypothesis that MMP-9 is a potential drug target for both COPD and MS and further development of highly potent and specific MMP-9 inhibitors is warranted.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 138-445 DRI_Approach denotes Matrix metalloproteinases (MMPs) are a large family of proteolytic enzymes involved in an array of physiological and pathological processes from development, morphogenesis, reproduction, wound healing, and aging to inflammation, angiogenesis, neurological disorders, and cancer cell invasion and metastasis.
T2 446-594 DRI_Challenge denotes The imbalance between MMP activity and the inhibitory action of tissue inhibitors of metalloproteinases (TIMPs) are implicated in multiple diseases.
T3 595-921 DRI_Approach denotes Secreted in the body in a latent form, upon activation MMP-9 (gelatinase B) acts on many inflammatory substrates, and thus is suspected of contributing to the progression of cardiovascular disease, rheumatoid arthritis, and the subjects of this review, chronic obstructive pulmonary disease (COPD) and multiple sclerosis (MS).
T4 922-989 DRI_Approach denotes COPD is the fourth most common cause of death in the United States.
T5 990-1055 DRI_Background denotes In COPD, increased expression of MMP-9 by inflammatory cells e.g.
T6 1056-1149 DRI_Challenge denotes neutrophils and macrophages is correlated with a variety of processes that cause lung damage.
T7 1150-1315 DRI_Outcome denotes MMP-9 is also important in cytokine and protease modulation; it degrades the serine protease inhibitor alpha(1)-antitrypsin, which thus may lead to lung destruction.
T8 1316-1395 DRI_Approach denotes MS affects approximately 400,000 Americans and over a million people worldwide.
T9 1396-1612 DRI_Challenge denotes Upregulation of MMP-9 increases the permeability of the blood brain barrier (BBB), facilitates the infiltration of leukocytes into the central nervous system, and causes myelin sheath degradation and neuronal damage.
T10 1613-1700 DRI_Outcome denotes Early stage clinical trials have shown promising results when MMP-9 is inhibited in MS.
T11 1701-1886 DRI_Challenge denotes These observations lead to the hypothesis that MMP-9 is a potential drug target for both COPD and MS and further development of highly potent and specific MMP-9 inhibitors is warranted.